News

Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show. “As the longest-running amantadine study to date,…

RTB101, an investigational therapy being developed to treat Parkinson’s disease, is well-tolerated, can cross the blood-brain barrier, and reaches potentially therapeutic concentrations in cerebrospinal fluid (CSF), according to interim results of a Phase 1b/2a study. Developed by resTORbio, RTB101 is an orally-administered compound meant…

Oncodesign and Servier have reached the first key milestone months ahead of schedule in their partnership to develop LRRK2 inhibitors for Parkinson’s disease, the companies announced in a press release. “The collaboration works perfectly and both teams are up to the challenges,” said Philippe Genne, PhD,…

A trial in Australia will test a motion machine, called the Reviver, to understand whether it can improve balance, mobility and sensory-motor coordination in people with moderate to advanced Parkinson’s disease and atypical parkinsonism. Exercise has been shown to help ease Parkinson’s symptoms. The Reviver machine,…

Mexico’s Federal Commission for the Protection against Sanitary Risk (COFEPRIS) has granted approval for the first in-human clinical trial of Zhittya Genesis Medicine‘s (ZGM)’s investigational therapy for Parkinson’s disease. Parkinson’s is characterized by the death of dopamine-producing neurons in the brain. A hypothesis that has gained traction in…

A majority of Parkinson’s patients in a clinical trial reported achieving a fully “on” response within 30 minutes of taking Sunovion‘s under-the-tongue apomorphine film, called APL-130277, about three months after starting its use to counter “off” episodes in this disease, a post-hoc analysis of study results…

Through Louisiana Tech University‘s (LTU) Student Scholar program, participants are both learning and teaching others about Parkinson’s disease (PD) and available support. Lauren Tompkins is one of two students currently in the program at LTU’s Parkinson Resource Center (PRC), which aims to promote a healthy PD community…

Using a light-activated protein to improve the function of mitochondria — cells’ powerhouses— could be a therapeutic strategy for Parkinson’s disease (PD), a new study done in flies suggests. The results of the study, “Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a…

Cure Parkinson’s Trust (CPT) and the Van Andel Institute (VAI) will contribute $4.5 million in total to support a global program that seeks to develop disease-modifying Parkinson’s therapies. The three-year funding agreement backs the international Linked Clinical Trials (LCT) initiative, established by the two organizations in 2012…

Increasing evidence links insulin-like growth factor 1 (IGF-1) deficiency to the development and progression of Parkinson’s disease, a review study said. Estrogen, the female sex hormone thought to hold potential beneficial effects against Parkinson’s, or PD, may exert its protective actions via IGF-1, the researchers said.